Axon Enterprise (NASDAQ:AXON) Stock Rating Upgraded by Morgan Stanley

Morgan Stanley upgraded shares of Axon Enterprise (NASDAQ:AXON) from an equal weight rating to an overweight rating in a research report report published on Tuesday morning, Marketbeat.com reports. They currently have $700.00 target price on the biotechnology company’s stock, up from their prior target price of $500.00.

Several other brokerages also recently issued reports on AXON. Needham & Company LLC raised their price target on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. The Goldman Sachs Group increased their price objective on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Northland Securities boosted their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Craig Hallum increased their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, JMP Securities boosted their price objective on shares of Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $460.33.

Axon Enterprise Trading Up 5.3 %

NASDAQ:AXON opened at $669.87 on Tuesday. The company’s 50 day moving average is $493.10 and its 200-day moving average is $382.63. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 12 month low of $229.02 and a 12 month high of $675.47. The firm has a market cap of $51.08 billion, a price-to-earnings ratio of 171.90, a P/E/G ratio of 14.00 and a beta of 1.01.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total value of $12,123,000.00. Following the transaction, the president now owns 208,166 shares of the company’s stock, valued at approximately $126,179,820.90. The trade was a 8.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Julie A. Cullivan sold 900 shares of Axon Enterprise stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the transaction, the director now directly owns 3,653 shares of the company’s stock, valued at $1,291,445.09. This represents a 19.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 135,256 shares of company stock worth $61,043,370 in the last 90 days. 5.70% of the stock is owned by company insiders.

Institutional Trading of Axon Enterprise

Hedge funds have recently modified their holdings of the stock. Quent Capital LLC boosted its stake in Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC boosted its position in shares of Axon Enterprise by 115.8% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares during the period. Brooklyn Investment Group bought a new stake in Axon Enterprise in the third quarter valued at about $41,000. Finally, Planning Capital Management Corp boosted its holdings in Axon Enterprise by 83.3% during the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock worth $48,000 after buying an additional 55 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.